ACE and hydrops fetalis: These beneficial effects on CRF, fit well with the overall favorable effects of sacubitril/valsartan on major adverse cardiovascular events and cardiac death in the Prospective Comparison of ARNI (Angiotensin Receptor-Neprilysin Inhibitor) with ACEI (Angiotensin-Converting-Enzyme Inhibitor) to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial (48).